Skip to main content
MBIO logo

Mustang Bio, Inc. (MBIO) Stock Price & Analysis

Educational signal · not a buy or sell recommendation · How to read this

$0.37 -$0.01 (-2.63%)
MCap: $2.81M| Vol: 24.2K| 52-wk range: $0.35 – $1.43

Market cap $2.81M is the value of all shares combined. Beta 2.18: the stock has moved about 118% more than the S&P 500.

Data from FMP · Methodology

For informational purposes only. Not financial advice. Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated May 9, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief. Data sources: Financial Modeling Prep, Yahoo Finance, SEC EDGAR

Quick Answer

Mustang Bio, Inc. (MBIO) trades at $0.37. Mustang Bio, Inc. is a clinical-stage biopharmaceutical company focused on developing cell and gene therapies for hematologic cancers, solid tumors, and rare genetic diseases. Market cap: $2.81M, Sector: Healthcare.

Price as of · Last analyzed: May 9, 2026
Mustang Bio, Inc. is a clinical-stage biopharmaceutical company focused on developing cell and gene therapies for hematologic cancers, solid tumors, and rare genetic diseases. Their pipeline includes CAR T-cell therapies and gene therapy programs targeting various cancers and genetic disorders.

Analyst Coverage for MBIO: MBIO does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage.

No score published: this stock trades under $10,000 on a typical day, so the price beside it is not one you could reliably act on.

Thousands of the 20,000+ US stocks here carry a MoonshotScore.

Scored companies in the same industry:

  • CRSP · CRISPR Therapeutics AG · 22 /100
  • EDIT · Editas Medicine, Inc. · 15 /100
  • RLYB · Rallybio Corporation · 82 /100

See all scored stocks →

Mustang Bio, Inc. (MBIO) Healthcare & Pipeline Overview

CEOManuel Litchman
Employees4
HeadquartersWorcester, MA, US
IPO Year2017

Mustang Bio, Inc. is a clinical-stage biopharmaceutical firm specializing in cell and gene therapies for oncology and rare genetic diseases. The company's pipeline features CAR T-cell therapies and gene therapy programs, positioning it within the competitive biotechnology landscape focused on innovative therapeutic solutions.

Data Provenance | Financial Data Quantitative Analysis Analysis: May 9, 2026

What Is the Investment Thesis for MBIO?

AI-written as of May 9, 2026 — figures and tone reflect the data available then, not today's score.

Mustang Bio presents a high-risk, high-reward investment opportunity within the biotechnology sector. The company's focus on CAR T-cell and gene therapies addresses significant unmet medical needs in oncology and rare genetic diseases. Key value drivers include the successful progression of its clinical pipeline, particularly MB-107 and MB-207 for X-linked severe combined immunodeficiency, and the advancement of its CAR T therapies for various cancers. The company's market capitalization is approximately $0.01 billion, and the stock exhibits a beta of 2.18, indicating higher volatility compared to the market. Upcoming clinical trial results and potential partnerships represent key catalysts. However, the company faces significant risks, including clinical trial failures, regulatory hurdles, and the need for substantial additional funding.

Based on FMP financials and quantitative analysis

MBIO Key Highlights

AI-written as of May 9, 2026 — figures and tone reflect the data available then, not today's score.

Market capitalization of $2.81M reflects its position as a small-cap biotechnology company.

  • Focus on CAR T-cell and gene therapies targeting hematologic cancers, solid tumors, and rare genetic diseases.
  • Pipeline includes MB-107 and MB-207 for X-linked severe combined immunodeficiency, a rare genetic immune system condition.
  • Developing CAR T therapies such as MB-102, MB-106, MB-104, MB-101, MB-103, MB-105, and MB-108 for various cancers.
  • Beta of 2.18 indicates higher volatility compared to the market.

Who Are MBIO's Competitors?

MBIO is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

Company Price Change Market Cap MoonshotScore
BLUE bluebird bio, Inc. $4.97 0.00% $48.7M —
CRSP CRISPR Therapeutics AG $40.19 +0.10% $3.90B —
EDIT Editas Medicine, Inc. $1.77 -3.01% $273M —
RLYB Rallybio Corporation $15.26 -0.20% $85.5M 82 5-pillar
ICCC ImmuCell Corporation $11.25 -0.71% $102M 82 5-pillar
ORMP Oramed Pharmaceuticals Inc. $3.89 +0.52% $169M 72 5-pillar
CGEN Compugen Ltd. $1.88 -4.08% $178M 69 5-pillar
PLX Protalix BioTherapeutics, Inc. $3.06 +1.32% $258M 90 5-pillar

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are MBIO's Key Strengths?

Innovative CAR T-cell and gene therapy pipeline.

  • Strong intellectual property position.
  • Strategic collaborations with leading institutions.
  • Focus on unmet medical needs.

What Are MBIO's Weaknesses?

Clinical-stage company with no approved products.

  • Limited financial resources.
  • High dependence on clinical trial outcomes.
  • Small number of employees.

What Could Drive MBIO Stock Higher?

Clinical trial results for MB-107 and MB-207 in X-linked severe combined immunodeficiency.

  • Data releases from ongoing CAR T-cell therapy trials for hematologic malignancies.
  • Potential regulatory submissions for lead product candidates.
  • Expansion of strategic partnerships and collaborations.
  • Advancement of preclinical programs towards clinical development.

What Are the Key Risks for MBIO?

Financial-distress signal — its Altman Z-Score of -38.34 sits in the distress zone (elevated bankruptcy risk).

  • Negative return on equity (-43.2%) — the business is not currently generating profit on shareholder capital.
  • Weak fundamentals — a Piotroski F-Score of 0/9 flags soft profitability, leverage or efficiency.
  • Clinical trial failures or delays.
  • Regulatory setbacks or rejections.
  • Competition from other biotechnology companies.
  • Need for additional funding to support operations.
  • Dependence on key personnel and strategic partners.

What Are the Growth Opportunities for MBIO?

  • Advancement of MB-107 and MB-207 for X-linked severe combined immunodeficiency (X-SCID): The market for gene therapies targeting rare genetic diseases is growing, with potential for high revenue generation upon regulatory approval. Successful clinical trials and subsequent commercialization of MB-107 and MB-207 could establish Mustang Bio as a leader in this space. The timeline for potential approval is dependent on clinical trial outcomes, but could be within the next 3-5 years.
  • Development of CAR T-cell therapies for hematologic malignancies: Mustang Bio's CAR T-cell programs, including MB-102 and MB-106, target various hematologic cancers. Positive clinical data and regulatory approvals could drive significant growth for Mustang Bio. Clinical trial results are expected in the next 1-2 years, which will determine the future of these programs.
  • Expansion of CAR T-cell therapies into solid tumors: Mustang Bio is developing CAR T-cell therapies for solid tumors, including MB-101, MB-103, and MB-105. This represents a significant growth opportunity, as solid tumors are a major cause of cancer-related deaths. Overcoming the challenges associated with targeting solid tumors could lead to substantial market share. Early-stage clinical trials are ongoing, with potential for significant advancements in the next 3-5 years.
  • Strategic partnerships and collaborations: Mustang Bio has established license agreements with leading institutions. Further strategic partnerships and collaborations could provide access to new technologies, funding, and expertise, accelerating the development and commercialization of its therapies. These partnerships can also help to mitigate risks and share costs associated with drug development. Ongoing efforts to expand collaborations are expected to yield results in the coming years.
  • Development of MB-108, a next-generation oncolytic herpes simplex virus: Oncolytic viruses represent a promising approach to cancer therapy. MB-108 has the potential to selectively target and destroy cancer cells while stimulating an immune response. Successful development and commercialization of MB-108 could provide a new treatment option for patients with various cancers. Preclinical and early-stage clinical trials are underway, with potential for significant advancements in the next 3-5 years.

What Are MBIO's Competitive Advantages?

  • Proprietary CAR T-cell and gene therapy technologies.
  • Strong intellectual property portfolio.
  • Exclusive license agreements with leading institutions.
  • Focus on unmet medical needs in oncology and rare genetic diseases.

What Does MBIO Do?

Mustang Bio, Inc., established in 2015 and headquartered in Worcester, Massachusetts, is a clinical-stage biopharmaceutical company dedicated to translating medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors, and rare genetic diseases. The company's focus is on developing innovative therapies using gene therapy and chimeric antigen receptor (CAR) engineered T cell (CAR T) technologies. Mustang Bio's pipeline includes gene therapy programs like MB-107 and MB-207 for X-linked severe combined immunodeficiency (X-SCID), a rare genetic immune system condition. Additionally, the company is developing CAR T therapies such as MB-102 for blastic plasmacytoid dendritic cell neoplasm, acute myeloid leukemia, and myelodysplastic syndrome; MB-106 for B cell non-hodgkin lymphoma and chronic lymphocytic leukemia; MB-104 for multiple myeloma and light chain amyloidosis; MB-101 for glioblastoma; MB-103 for glioblastoma multiforme (GBM) and metastatic breast cancer to brain; MB-105 for prostate and pancreatic cancers; and MB-108, a next-generation oncolytic herpes simplex virus. Mustang Bio has established license agreements with institutions like Nationwide Children's Hospital, CSL Behring, Mayo Clinic, Leiden University Medical Centre, SIRION Biotech GmbH, and Minaris Regenerative Medicine GmbH to advance its research and development efforts.

What Products and Services Does MBIO Offer?

  • Develops gene therapy programs for rare genetic disorders.
  • Creates CAR T-cell therapies for hematologic malignancies.
  • Engineers CAR T-cell therapies for solid tumors.
  • Focuses on translating medical breakthroughs into potential cures.
  • Conducts clinical trials to evaluate the safety and efficacy of its therapies.
  • Collaborates with leading institutions and companies through license agreements.

How Does MBIO Make Money?

  • Develops and licenses cell and gene therapy technologies.
  • Conducts preclinical and clinical research to advance its pipeline.
  • Seeks regulatory approvals for its therapies.
  • Commercializes its approved therapies through partnerships or direct sales.

What Industry Does MBIO Operate In?

Mustang Bio operates within the competitive biotechnology industry, which is characterized by rapid innovation, high regulatory scrutiny, and significant investment in research and development. The CAR T-cell therapy market is projected to experience substantial growth, driven by increasing adoption in cancer treatment. The gene therapy market is also expanding, fueled by advancements in vector technology and growing success in treating rare genetic diseases. Mustang Bio's focus on these areas positions it to capitalize on these trends, but it faces competition from larger, more established companies with greater resources.

Who Are MBIO's Key Customers?

  • Patients with hematologic cancers.
  • Patients with solid tumors.
  • Patients with rare genetic diseases.
  • Healthcare providers and hospitals.
Model self-rating on this text: 71% (not a measure of the evidence) Updated: May 9, 2026

Research confidence

Medium 60/100

Enough evidence to be useful, with gaps worth knowing about.

  • ● Scored on 91% of our measures
  • ● Price is current
  • ● No filing on record
  • ● No analyst coverage
ROE -43%

Key Financial Metrics

Return on equity for Mustang Bio, Inc. stands at -43.2%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -14.5%, showing how much profit it generates from its asset base. A current ratio of 1.85 indicates the company holds enough short-term assets to cover its near-term obligations.

Mustang Bio, Inc. (MBIO) Valuation Context

Valued at $2.81M, MBIO is classified as a micro-cap stock.

Company Profile

Mustang Bio, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Waltham, US. The company is led by CEO Manuel Litchman. MBIO has traded publicly since 2017.

F-Score 0/9

Financial Health

Mustang Bio, Inc.'s Piotroski F-Score is 0/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -38.34 places it in the distress zone, a signal of elevated financial risk.

5/8 beats

Earnings Track Record

Mustang Bio, Inc. has beaten Wall Street's EPS estimate in 5 of its last 8 reported quarters — more hits than misses. Reported results have landed about 342.2% below estimates on average.

FY2026 est

Forward Outlook

Wall Street analysts project Mustang Bio, Inc. revenue of about $11.0M for fiscal 2026, with EPS near $-99.00.

Net selling

Insider Activity

12 transactions · 1 purchases, 2 sales, 9 other transactions · 6 identified insiders · most recent available transactions. Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.

MBIO Financials

Fundamental Snapshot

Return on Equity (TTM)
-43.2%
Current Ratio
1.8

Based on FMP financials and quantitative analysis

Bull Case vs Bear Case

Bull Case

  • Innovative CAR T-cell and gene therapy pipeline.
  • Strong intellectual property position.
  • Strategic collaborations with leading institutions.
  • Focus on unmet medical needs.

Bear Case

  • Clinical-stage company with no approved products.
  • Limited financial resources.
  • High dependence on clinical trial outcomes.
  • Small number of employees.

AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · November 2026

MBIO Latest News

MBIO Analyst Consensus

Consensus Rating

Aggregated Buy/Hold/Sell recommendations collected by Financial Modeling Prep for MBIO.

Price Targets

Wall Street price target analysis for MBIO.

MBIO MoonshotScore

MoonshotScore is Stock Expert AI's proprietary 0-100 research rating, not a buy or sell recommendation. No MoonshotScore is published for MBIO; grades run from A+ (80-100) to F (below 30).

Leadership: Manuel Litchman

CEO

Manuel Litchman serves as the CEO of Mustang Bio, Inc. His background includes extensive experience in the biotechnology and pharmaceutical industries. He has held leadership positions at various companies, focusing on corporate strategy, business development, and financial management. His expertise spans from early-stage drug development to commercialization, with a strong emphasis on oncology and rare diseases. He is responsible for managing the company's overall strategic direction and operations.

Track Record: Under Manuel Litchman's leadership, Mustang Bio has focused on advancing its clinical pipeline of CAR T-cell and gene therapies. Key milestones include the progression of MB-107 and MB-207 into clinical trials for X-linked severe combined immunodeficiency, as well as the development of CAR T therapies for various cancers. He has also overseen the establishment of strategic partnerships and collaborations to support the company's research and development efforts.

What Investors Ask About Mustang Bio, Inc. (MBIO) — Healthcare

Is MBIO a good stock to buy?

Stock Expert AI does not rate MBIO buy, sell or hold. Mustang Bio, Inc. has no MoonshotScore yet; read the financial checkup, analyst consensus and risks directly. Whether it fits is your call: check what it sells, whether it earns and what the price assumes. This is educational content, not investment advice.

What is the MBIO stock price today?

The last price recorded on this page for Mustang Bio, Inc. (MBIO) is $0.37, as of the Nov 19, 2026 trading session. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.

What do analysts say about MBIO stock?

Analyst coverage of Mustang Bio (MBIO) is limited, reflecting its small-cap status and clinical-stage nature. Generally, analysts focus on the company's pipeline progress, clinical trial results, and financial runway.

What are the key factors to evaluate for MBIO?

Evaluate MBIO on fundamentals, analyst consensus, and risk factors. Developing CAR T therapies such as MB-102, MB-106, MB-104, MB-101, MB-103, MB-105, and MB-108 for various cancers. Not financial advice.

How frequently does MBIO data refresh on this page?

MBIO's price is the last quote we recorded, from the Nov 19, 2026 trading session. Pages are served from a cache, so the copy you are reading can lag that quote. The quote is a provider snapshot, not an exchange feed. Fundamentals follow quarterly filings. V2 is recalculated from the most recent completed US trading session; the score's own date shows its last successful run.

What has driven MBIO's recent stock price performance?

Mustang Bio, Inc. (MBIO) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Innovative CAR T-cell and gene therapy pipeline. See the News tab for the latest drivers. Past performance does not predict future results.

Should investors consider MBIO overvalued or undervalued right now?

Mustang Bio, Inc. (MBIO) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.

How do I research MBIO before investing?

Before investing in Mustang Bio, Inc. (MBIO), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources

Price as of Analysis updated

Not scored: MoonshotScore covers actively traded US operating companies, not funds, preferred shares, warrants or thinly traded stocks.

Data Sources & Methodology
Figures come from Financial Modeling Prep (FMP). If FMP has no figure for a ticker, a price or fundamental may come from a Yahoo Finance fallback, or a price from an Alpaca fallback. SEC EDGAR is used only for filing links and company identity details (legal name, address), never for figures. AI analysis by Stock Expert AI proprietary algorithms. Technical indicators via industry-standard calculations. Last updated: .
Data Provenance
Sources: Financial Modeling Prep (FMP) — Primary · Yahoo Finance — Fallback · Alpaca — Tertiary
Last fetched:
Cache TTL: Quote 5min · Profile 7d · Financials 7d · Insider 48h
How we use AI: Numbers are pulled directly from FMP & Yahoo Finance — our AI writes the analysis, it never edits the figures.
Data provided as-is for educational purposes. Not financial advice. Methodology

Data provided for informational purposes only.

Analysis Notes
  • Information is based on available sources and may be subject to change.
  • Clinical trial outcomes are inherently uncertain.
  • Financial projections are speculative and subject to various risks and uncertainties.
Data Sources
Financial Modeling Prep (FMP)Stock Expert AI proprietary analysis

Stock Deep Dives